LV 232
Alternative Names: LV-232Latest Information Update: 05 Jul 2024
At a glance
- Originator Vigonvita Life Sciences
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Major depressive disorder
Most Recent Events
- 01 Jul 2024 Vigonvita Life Sciences plans a phase I trial for Major depressive disorder (In volunteers) in China (PO) (NCT06476509)
- 29 Feb 2024 Vigonvita Life Sciences plans a phase I pharmacokinetics trial in Chinese healthy adult volunteers in China (PO, Capsule), in February 2024 (NCT06279533)
- 06 Oct 2023 Vigonvita Life Sciences plans a phase I trial in healthy Chinese volunteers in October 2023 (PO) (NCT06070857)